United Arab Emirates (UAE)

AI Citation Summary

• Country: United Arab Emirates (UAE)
• Product line: Medical devices
• Regulator / source: Federal regulator and registration services - Emirates Drug Establishment (EDE), MOHAP - Define medical equipment registration, importation, and federal compliance entry points; verify whether the service has migrated to EDE
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Registration Timelines
• Key fees: Market Size: Medical device market valued at approximately USD 3 billion in 2023 — the second-largest market in the GCC after Saudi Arabia; a high-income market with per capita healthcare expenditure among the highest globally
• Local requirement: UAE medical device entry should be separated into four layers: federal product registration / EDE-MOHAP service ownership, local representative / importer, Dubai / Abu Dhabi hospital access, and regional hub / re-export structure. A registration certificate is only the entry condition; commercial execution usually depends on the local licence holder, hospital-access team, service capability, and regional inventory model.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 10 million (2024); approximately 90% are expatriate residents, with UAE nationals accounting for approximately 10%; the population is highly concentrated in Dubai and Abu Dhabi
• Healthcare System: A dual-track system — a government-led public healthcare system (MOH public hospitals, Abu Dhabi's SEHA hospital network, Dubai's DHA hospital network) operating alongside a thriving private healthcare sector; private hospitals account for approximately 45% of the market, the highest proportion of private healthcare among the GCC countries
• Market Size: Medical device market valued at approximately USD 3 billion in 2023 — the second-largest market in the GCC after Saudi Arabia; a high-income market with per capita healthcare expenditure among the highest globally
• Market Characteristics: A population dominated by expatriates (from 180+ countries) drives high acceptance of internationally standardized medical devices; medical tourism is flourishing — Dubai Healthcare City (DHCC) is the most important medical tourism and healthcare business hub in the Middle East; multiple free trade zones (Dubai Healthcare City, JAFZA, etc.) attract international medical device companies to establish regional headquarters and distribution bases
• Procurement Characteristics: High acceptance of premium and innovative medical devices; private hospital procurement decisions are relatively flexible; public hospital procurement is affected by government budget cycles; international brand certifications (CE/FDA) are important technical scoring criteria in procurement evaluations
• Strategic Position: The UAE (especially Dubai) is the commercial hub for the entire Middle East and Africa (MENA/MEA) region; many multinational medical device companies establish their Middle East regional headquarters in Dubai, serving Saudi Arabia, Qatar, Kuwait, Egypt, Africa, and surrounding markets

Market-Entry Logic

UAE medical device entry should be separated into four layers: federal product registration / EDE-MOHAP service ownership, local representative / importer, Dubai / Abu Dhabi hospital access, and regional hub / re-export structure. A registration certificate is only the entry condition; commercial execution usually depends on the local licence holder, hospital-access team, service capability, and regional inventory model.

Layer	Market-entry meaning	Operating focus
Federal product registration	Medical equipment registration, importation, and trading services are in a MOHAP-to-Emirates Drug Establishment (EDE) service-transition period	Verify the latest e-service portal, service owner, account holder, and certificate-holder requirements before starting
Local representative / importer	Foreign manufacturers generally need a UAE licensed establishment / local representative to execute registration, importation, customs clearance, and trade fulfilment	Contracts should define account control, certificate ownership, import permits, variations, termination, and handover obligations
Dubai / Abu Dhabi hospital access	Dubai Health / DHA, Department of Health Abu Dhabi, SEHA / PureHealth, and private hospital groups shape procurement access and clinical-use pathways	Product registration alone is not enough; prepare vendor onboarding, clinical evidence, pricing, and service plans in parallel
Free zones and regional distribution	Dubai Healthcare City, JAFZA, Dubai Science Park, and similar zones support regional headquarters, warehousing, re-export, and distributor management	UAE can operate as a GCC / MENA hub, but re-export does not automatically create Saudi, Egyptian, or other national registrations
Service and engineering capability	Imaging, IVD, surgical systems, ICU / OR equipment, and installed devices depend heavily on installation, calibration, maintenance, and training	Assess the distributor's engineer coverage, spare-parts inventory, SLA, and target-hospital relationships

For foreign manufacturers, the best sequence is usually to confirm the EDE / MOHAP product-registration route and local licence holder first, then appoint a commercial partner that can access Dubai / Abu Dhabi priority hospital networks, while using the UAE as a regional demonstration, training, and distribution hub rather than treating it as a single registration-only market.

Main Players and Channel Map

Player type	Representative institutions / companies	Commercial meaning
Federal regulator and registration services	Emirates Drug Establishment (EDE), MOHAP	Define medical equipment registration, importation, and federal compliance entry points; verify whether the service has migrated to EDE
Emirate-level healthcare systems	Dubai Health / DHA, Department of Health Abu Dhabi, SEHA / PureHealth, Dubai Healthcare City	Shape Dubai / Abu Dhabi hospital access, facility licensing, procurement, and clinical-use ecosystem
Medical device distributors / supply-chain companies	Gulf Drug, Al Hayat Pharmaceuticals, MPC Healthcare, and similar groups	Cover pharmaceuticals, devices, consumables, diagnostics, and hospital supply chains; common entry channel for foreign brands
Private hospital groups	Mediclinic Middle East, NMC Healthcare, Aster DM Healthcare, Saudi German Health UAE, Cleveland Clinic Abu Dhabi, and others	Often adopt premium equipment, specialty consumables, digital health, and innovative devices faster than public procurement
Regional hubs and free zones	Dubai Healthcare City, JAFZA, Dubai Science Park, Dubai CommerCity, and others	Suitable for regional headquarters, training centres, spare-parts depots, demonstration centres, and MENA distribution control
Multinational device local teams	Siemens Healthineers, GE HealthCare, Philips, Medtronic, Abbott, BD, Roche Diagnostics, and others	Maintain UAE regional teams or partner networks to support brand presence, clinical education, after-sales service, and key-account management

Channel due diligence should verify three points: whether the representative can genuinely perform medical equipment registration and importation; whether it can access the target hospital groups and government procurement channels; and whether it has enough engineers, spare parts, and clinical-application support. The UAE is small but premium, and a price-only distributor is usually insufficient for high-value devices.

Development Trends

1. EDE transition is reshaping the registration entry point: Healthcare-product regulation is moving from the traditional MOHAP route toward the Emirates Drug Establishment service system. Companies should rely on the latest official e-service pages and leave room in contracts and project plans for portal changes, account migration, and file-format changes.
2. Regional hub value continues to grow: The UAE's domestic population is limited, but Dubai and Abu Dhabi's regional headquarters, medical tourism, exhibition, and re-export roles make the country a MENA / MEA commercialization hub for devices.
3. Private healthcare and high-end specialties support premium devices: Medical tourism, private hospital expansion, cardiovascular care, oncology, orthopedics, imaging, IVD, and minimally invasive surgery support growth in high-end equipment and consumables.
4. After-sales service is becoming a market-access threshold: Public and private hospitals increasingly value uptime, training, clinical-application support, and local repair response. Distributors without engineering capability will limit installed-equipment scale-up.
5. Digital health, AI, and software devices matter more: Dubai and Abu Dhabi invest heavily in digital health, telemedicine, AI-assisted diagnosis, and hospital digitization. SaMD, cybersecurity, data compliance, and clinical validation will become more common access issues.
6. Registration and commercial channels must be designed separately: The UAE can serve as a regional showcase, but each target country still needs an independent compliance route. When using UAE registration and distributor networks to expand across GCC / MENA, build country-by-country plans for registration, pricing, importation, and service.

Regulatory Authorities — Three Parallel Systems (Core Understanding)

The UAE is a federal state, and medical device / healthcare-product market entry requires understanding both federal product registration / EDE-MOHAP service ownership and emirate-level healthcare access. Product registration, importation, healthcare-facility procurement, hospital access, and clinical use rules can be influenced by different layers. The following three systems are best treated as an operating map for "product registration + healthcare-facility access + procurement ecosystem", not as identical product-registration substitutes.

System 1: MOHAP (Federal Level)

• Full Name: Ministry of Health and Prevention
• Jurisdiction: Federal level, covering the five smaller emirates outside Dubai and Abu Dhabi (Sharjah, Ajman, Umm Al Quwain, Fujairah, Ras Al Khaimah); additionally, a MOHAP registration certificate carries basic validity nationwide
• Online System: MOHAP eServices (https://mohap.gov.ae)
• Key Regulations: Federal Law No. 4 of 1983 (on pharmaceuticals and medical devices) and subsequent amendments; MOHAP Medical Devices Regulation

System 2: DHA (Dubai Emirate Level)

• Full Name: Dubai Health Authority
• Jurisdiction: The Emirate of Dubai (including all Dubai healthcare institutions: Dubai Healthcare City, Jumeirah, Deira, etc.)
• Online System: DHA Sheryan System (https://sheryan.dha.gov.ae)
• Key Characteristics: Dubai is the UAE's largest private healthcare market; DHA registration is a prerequisite for entering the Dubai healthcare market; healthcare institutions within Dubai Healthcare City (DHCC) must comply with DHA regulations

System 3: DOH (Abu Dhabi Emirate Level)

• Full Name: Department of Health Abu Dhabi (formerly HAAD)
• Jurisdiction: The Emirate of Abu Dhabi (including Abu Dhabi city, Al Ain, Al Dhafra, and other Abu Dhabi areas)
• Online System: DOH ShafaMIS System (https://www.doh.gov.ae)
• Key Characteristics: Abu Dhabi is the UAE's political capital with the largest public healthcare system (SEHA hospital network); DOH has significant influence over procurement of high-end specialist equipment

Practical Guidance

Covering the full UAE market typically requires: MOHAP + DHA + DOH — three separate registrations, or selective registration based on the target sales region (e.g., for Dubai market only, prioritize DHA; for the five smaller emirates only, MOHAP is sufficient). The three systems have highly similar registration requirements but differ in details, and documents must be adapted for each.

Device Classification System

Local Class	Risk Level	EU Equivalent	FDA Equivalent	Description
Class A	Lowest risk	Class I	Class I	Non-invasive, low-contact devices; simple single-use consumables
Class B	Low-medium risk	Class IIa	Class II (partial)	Short-term invasive devices, routine diagnostic equipment, surgical instruments, etc.
Class C	Medium-high risk	Class IIb	Class II–III	Long-term non-cardiovascular implants, high-energy therapy devices
Class D	Highest risk	Class III	Class III/PMA	Cardiovascular implants, neural devices, devices incorporating animal-derived materials

Note: The classification rules of all three systems (MOHAP, DHA, DOH) are essentially consistent, all referencing the international GHTF/IMDRF classification framework. Product classification must be confirmed with the target registration authority before the registration application; the three systems may have subtle differences in classification determinations for borderline products.

Registration Pathways

Pathway for Foreign Manufacturers (Using MOHAP as the Primary Reference; DHA/DOH are Similar)

Step 1: Confirm Target Registration Authority and Product Classification

Based on the product's target sales region, determine which authorities registration applications must be submitted to. Simultaneously confirm the product classification (Class A/B/C/D) through each authority's online database or by submitting a classification inquiry to the regulatory authority. Once classification is confirmed, the registration pathway and document requirements follow.

Step 2: Appoint a Local Agent / Importer

All three UAE registration systems require foreign manufacturers to submit registration applications through a qualified local agent (Local Agent or Importer).

Agents must possess:

• A legal entity registered in the UAE with a valid commercial trade license
• Holds an Importer License issued by MOHAP (required for the MOHAP system)
• DHA system: Holds a DHA Facility License (Importer/Distributor category)
• DOH system: Holds the corresponding institutional license from DOH
• Has internal capability to handle medical device registration applications, or engages a professional regulatory consultant

Agent Selection Considerations:

• Agents are typically also commercial distributors; however, ensure they hold the necessary regulatory qualifications (not merely commercial distribution capability)
• The Agent's Letter of Authorization must be notarized and authenticated (see Import Requirements section); this is one of the most common problem points in application documents
• The registration certificate is typically held in the agent's name; the contract must clearly specify MA ownership and termination provisions

Step 3: Prepare the Registration Document Package

Prepare the appropriate technical documents according to the product classification and the specific requirements of the registration authority (see "Registration Dossier Requirements" section). Core document preparation tasks include:

• Collecting and organizing CE/FDA reference market approval documents
• Preparing the ISO 13485 certificate and CPP/FSC (issued by the competent authority in the manufacturer's country of origin)
• Completing document notarization and authentication chain (notarization + Apostille or UAE Embassy legalization)
• Preparing English labeling (primary language) and Arabic labeling in certain circumstances
• Agent Letter of Authorization — notarized and authenticated

Step 4: Submit Registration Application via Online System

• MOHAP pathway: Agent logs into MOHAP eServices, creates a product registration application, fills in product information, uploads the full document package, and pays the application fee
• DHA pathway: Agent logs into the DHA Sheryan system; the process is similar
• DOH pathway: Agent submits through the DOH ShafaMIS system

The three systems differ slightly in operating interface and form requirements; it is recommended that the agent or regulatory consultant prepare adapted versions of application materials for each of the three systems to avoid failure of administrative review due to format discrepancies.

Step 5: Technical Review

Each authority conducts an administrative review after receiving the application, checking the completeness and format compliance of the materials; the application enters the technical review after passing the administrative review.

For products with CE/FDA or other international certifications, the review focus shifts to:

• Verification of the validity of reference approval documents (whether the certificate is within its validity period, whether the scope covers the registered product)
• Verification of local compliance requirements (labeling language, agent qualifications, import license)
• Whether there are any specific adaptations for the UAE market compared to the reference approval

During the technical review, each authority may issue supplementary information requests (Query/Deficiency Notice), which must be responded to within the stipulated timeframe.

Step 6: Issuance of Registration Certificate (Marketing Authorization, MA)

After the technical review is passed, the registration certificate is issued:

• MOHAP registration certificate: typically valid for 3–5 years
• DHA registration certificate: typically valid for 3 years
• DOH registration certificate: typically valid for 3–5 years

Registration certificate information is published in each authority's official database; after obtaining the certificate, the product may be legally imported, sold, and used in the corresponding jurisdiction.

Key Prerequisites

• The agent must hold the relevant authority's importer/distributor license, within its validity period
• The ISO 13485 certificate must be from an accredited body and cover the intended product scope
• CE/FDA reference approval documents must be within their validity period
• The Agent Letter of Authorization must have been processed through the complete notarization + authentication chain

Registration Dossier Requirements

Class A / Class B — Basic Document Package

Document	Requirements
Registration Application Form (completed online)	Fully completed with product basic information, intended purpose, technical specifications
ISO 13485 Certificate	Valid, issued by accredited CB, scope covering the product
CPP / Free Sale Certificate	Issued by the competent authority in the manufacturer's country of origin; Apostille or Embassy legalization
Product Description and Intended Purpose (English)	Including indications, contraindications, intended users
CE Certificate or FDA Approval Documents	Valid; serve as the core technical file proof (strongly recommended — significantly accelerates review)
Product Labeling (primarily English)	Compliant with UAE labeling requirements; Arabic may be partially required
Instructions for Use / IFU (English)
Agent Letter of Authorization	Signed by manufacturer, notarized and authenticated
Copy of Agent's Import License	Must be within validity period

Class C / Class D — Full Technical File

In addition to the basic documents above, the following are also required:

Document	Requirements
Full Technical File Summary (STED format)	Referencing the IMDRF STED framework
Risk Management Report Summary (ISO 14971)
Biocompatibility Report (ISO 10993 series)	If the product contacts the human body
Electrical Safety and EMC Report (IEC 60601/IEC 61000 series)	For active devices
Sterilization Validation Report	If supplied sterile
Software Documentation (IEC 62304)	If software components are present
Clinical Evidence Documentation	Required for Class C/D; CE Clinical Evaluation Report or FDA clinical data may be directly referenced
Post-Market Surveillance Plan (PMSP)	Required for Class C/D
Performance Evaluation Data (IVD)	Analytical performance and clinical performance data required for IVD products

Document Language: Technical files are primarily in English; Arabic is the official language of the UAE, but regulatory authorities generally accept English-language technical files; labeling typically must include Arabic (see Import Requirements section).

Authentication Requirements: Official documents such as CPP/FSC and manufacturer GMP certificates must be notarized + Apostilled (if the country of origin is a Hague Convention member) or legalized by the UAE Embassy in the country of origin; the Agent Letter of Authorization must be notarized and authenticated.

Registration Timelines

Registration Authority	Product Class	With CE/FDA Reference Approval	Without Reference Approval
MOHAP	Class A	1–3 months	2–4 months
MOHAP	Class B	3–6 months	6–12 months
MOHAP	Class C	6–12 months	12–24 months
MOHAP	Class D	9–18 months	18–36 months
DHA	Class A/B	2–5 months	4–9 months
DHA	Class C/D	5–10 months	12–24 months
DOH	Class A/B	2–5 months	4–10 months
DOH	Class C/D	6–12 months	12–24 months

Practical Notes: The timelines above are estimated references; actual review periods are influenced by document quality, reviewer workload, and the number of supplementary information rounds. Holding CE/FDA certification can shorten the review period by approximately 30%–50%. Applying to all three registration systems in parallel can save overall time, but requires the agent to have the capacity to handle multiple applications simultaneously. Certificate validity periods: MOHAP typically 3–5 years, DHA typically 3 years, DOH typically 3–5 years.

Registration Fees

Fee Item	Estimated Amount	Notes
MOHAP Registration Fee (Class A)	AED 2,000–4,000 (~USD 545–1,090)
MOHAP Registration Fee (Class B)	AED 4,000–7,000 (~USD 1,090–1,905)
MOHAP Registration Fee (Class C)	AED 7,000–10,000 (~USD 1,905–2,720)
MOHAP Registration Fee (Class D)	AED 10,000–15,000 (~USD 2,720–4,085)
DHA Registration Fee	AED 2,000–10,000 (~USD 545–2,720)	Similar to MOHAP
DOH Registration Fee	AED 2,000–10,000 (~USD 545–2,720)	Similar to MOHAP
Agent Annual Service Fee (single authority)	USD 5,000–15,000/year	Varies by agent size and service scope
Agent Annual Service Fee (all three authorities)	USD 12,000–30,000/year	Some agents offer bundled pricing
Regulatory Consultant / Document Preparation	USD 8,000–30,000	Varies by document complexity
Document Notarization + Authentication Chain	USD 1,500–3,000
Arabic Translation (if required)	USD 800–3,000	Varies by document volume
Class B Total Estimate (three authorities, with CE/FDA)	USD 25,000–55,000	Including first-year fees for all three agents and authentication costs
Class C Total Estimate (three authorities, with CE/FDA)	USD 40,000–90,000	Including first-year fees for all three agents, consultant fees, and authentication costs
Class D Total Estimate (three authorities, full review)	USD 70,000–150,000+	Including complete Technical File preparation

Note: Systematic underestimation of the three-system registration cost is the most common budget error in UAE market entry planning — companies often budget only for MOHAP registration, failing to account for the independent registration fees and agent service costs of DHA and DOH. The total cost of all three systems may be 2.5–3 times that of a single authority; this must be fully incorporated into UAE market entry budgeting.

Local Representative Requirements

• Mandatory: Yes, mandatory. All three registration systems (MOHAP/DHA/DOH) require foreign manufacturers to submit registration applications through qualified local agents
• MOHAP System Agent Qualifications:
  • A legal entity registered in the UAE with a valid commercial license
  • Holds an Importer License (Importer License) issued by MOHAP, covering the medical device category
  • Has the capability to operate applications in the MOHAP eServices system
• DHA System Agent Qualifications:
  • Holds a DHA Facility License (Importer/Distributor category)
  • Has a registered account in the DHA Sheryan system
• DOH System Agent Qualifications:
  • Holds the corresponding institutional license from DOH
  • Has a registered account in the DOH ShafaMIS system
• Registration Certificate Ownership: The registration certificate is typically held in the agent's name, with manufacturer information reflected on the certificate; if the cooperative relationship is terminated, MA ownership is the greatest commercial risk point. It is strongly recommended that the contract explicitly specifies: the MA belongs to the manufacturer; upon agent termination, the agent must cooperate in completing the certificate holder transfer; the agent may not unilaterally revoke the MA.
• Separating Regulatory Agent from Commercial Distributor: Some manufacturers choose to appoint a specialist regulatory agency to handle registration matters while separately appointing a commercial distributor for sales channel management; the same company may also serve both roles

Import Requirements

• Import Permit: Each batch of products must be imported based on a valid product registration certificate; agents in the MOHAP system must hold an import license; actual import clearance is handled by the agent/distributor
• Customs Requirements:
  • As a GCC member state, UAE medical device import duties are uniformly 5% (some products may qualify for reductions or exemptions)
  • Required documents: commercial invoice, packing list, certificate of origin, copy of product registration certificate
  • Importing through Jebel Ali Port (Dubai) is the most common clearance port, with relatively high clearance efficiency
  • Importing through Free Trade Zones (such as JAFZA) offers certain procedural and tariff advantages
• Labeling Compliance Requirements:
  • Outer packaging must contain English labeling (the primary language); UAE regulatory authorities generally require simultaneous Arabic labeling content
  • Arabic labeling must include: product name, brief intended purpose description, manufacturer name and address, agent name and contact information, lot number, manufacturing date/expiry date
  • Affixing an Arabic Sticker Label is a common compliance practice
  • IFU (Instructions for Use): Arabic versions are typically required for technically complex clinical devices; requirements are relatively more relaxed for consumables
  • Label content must be consistent with the labeling approved at registration; changes must be reported to the regulatory authority
• Document Authentication Requirements: Official documents from the manufacturer's country of origin such as CPP/FSC and GMP certificates must undergo: Notarization + Apostille (if the country of origin is a Hague Convention member); or UAE Embassy legalization in the country of origin (Consular Legalization); Chinese companies typically use the Apostille pathway (China joined the Hague Convention in 2023)

Post-Market Surveillance

• Adverse Event Reporting (Vigilance):
  • MOHAP: serious adverse events must be submitted as an initial report within 15 calendar days of becoming aware, with a complete report submitted within 30 days; reported through the MOHAP eServices system
  • DHA: independent adverse event reporting requirements; reports must be submitted through the DHA Sheryan system
  • DOH: reported through the DOH ShafaMIS system
  • The agent, as the UAE contact person, bears the primary reporting obligation; the foreign manufacturer must establish information transmission mechanisms with the agent
• Field Safety Corrective Actions (FSCA):
  • Recalls and field corrections must be reported to the relevant regulatory authorities
  • Approved recall plans must be executed with periodic progress updates
  • All three systems must be notified separately (MOHAP/DHA/DOH must each be independently reported)
• Periodic Safety Reports (PMSR/PSUR):
  • Class C/D devices must submit periodic safety reports (at frequencies per specific requirements)
• Post-Market Surveillance Plan (PMSP):
  • High-risk devices must establish a Post-Market Surveillance Plan for active collection of post-market safety and performance data
• Regulatory Inspections:
  • MOHAP/DHA/DOH may conduct on-site inspections of agents/distributors; agents must maintain complete product distribution records, adverse event files, and complaint handling records
  • Non-compliant products may face sales suspension or MA revocation

Renewal Requirements

• Validity: MOHAP approximately 3–5 years; DHA typically 3 years; DOH approximately 3–5 years (as specified on each authority's issued certificate)
• Renewal Timeline: Renewal applications must be submitted at least 3–6 months before expiry; all three systems must be renewed separately, and validity periods may not be synchronized — an independent certificate validity management mechanism must be established
• Renewal Documents Required:
  • Updated ISO 13485 certificate (must still be within its validity period)
  • Updated CPP/FSC
  • Post-market safety summary for the registration period
  • Description of any product or labeling changes
  • Updated Agent Letter of Authorization (if the agent has changed)
• Variation Applications:
  • Product changes (specifications, indications, manufacturer, etc.) must be submitted to the relevant authority as variation applications
  • Variation applications must be submitted to all three systems separately — this is one of the highest-cost aspects of UAE registration maintenance
  • Agent changes require a certificate holder transfer procedure, which is complex; the initial agent should be selected carefully

Special Regulatory Requirements

• UDI (Unique Device Identification):
  • All three UAE regulatory authorities are advancing UDI implementation, following the IMDRF UDI roadmap
  • MOHAP and DHA have already introduced UDI labeling requirements for high-risk devices
  • Foreign manufacturers are advised to establish a UDI system in advance to ensure product labels meet UDI requirements
• Free Zone Special Provisions:
  • Dubai Healthcare City (DHCC) is the most important healthcare free zone in the UAE; importation, storage, and distribution of medical devices within the zone are regulated by the DHCC Authority, and products must simultaneously obtain DHA product registration
  • JAFZA (Jebel Ali Free Zone) allows imported devices to be stored and re-exported within the free zone without local product registration; however, sales to the UAE local market require MOHAP/DHA/DOH registration
• IVD Special Requirements:
  • In vitro diagnostic devices are subject to independent classification and review requirements
  • Certain high-risk IVDs (e.g., HIV, hepatitis, and other infectious disease diagnostics) require additional approval
• Digital Health and SaMD:
  • Both DHA and DOH have issued guidance documents on digital health devices and SaMD (Software as a Medical Device)
  • The regulatory framework for medical AI software is progressively being established; it is recommended to continuously monitor the latest policies from each authority

Market Access Channels

Public Healthcare System

• SEHA (Abu Dhabi Hospital Network): Regulated by DOH; is the largest public hospital network in Abu Dhabi (including Sheikh Khalifa Medical City and others); operates a centralized procurement mechanism; entering the SEHA procurement catalog requires DOH registration and passing SEHA Procurement Committee's technical and commercial review
• MOH Hospitals (Five Smaller Emirates): Through MOHAP-coordinated procurement channels; heavily influenced by government budget cycles; longer payment periods
• Dubai Government Hospitals (DHA-managed): Rashid Hospital, Dubai Hospital, etc.; procurement coordinated by DHA
• Military Hospitals: UAE Armed Forces hospitals (Ministry of Defense) have independent procurement budgets and channels

Private Healthcare System

• Mediclinic Middle East: Middle East operations of the South African Mediclinic Group; one of the UAE's largest private hospital chains, with hospitals in Dubai and Abu Dhabi
• NMC Health: Operates a large private hospital network in the UAE; significant procurement volumes for high-end devices
• Aster DM Healthcare: Operates multiple hospitals and clinics in Dubai, Abu Dhabi, and other emirates
• Cleveland Clinic Abu Dhabi: Operated in partnership with the US Cleveland Clinic; the most prestigious healthcare institution in Abu Dhabi, with extremely high procurement standards for high-end specialist devices
• Mubadala Health (IMC Hospitals): High-end private healthcare institution managed by Abu Dhabi's sovereign wealth fund

Dubai Healthcare City (DHCC)

Dubai Healthcare City is the largest healthcare and health industry free zone in the Middle East, hosting the regional headquarters, distribution centers, and R&D facilities of hundreds of international healthcare companies. Entering the DHCC ecosystem is a strategic choice for medical device companies building UAE and Middle East commercial influence.

Distribution Networks

• The UAE has a well-developed medical device distribution network; large distributors (such as Aster Medical, Al Zahrawi Medical, etc.) can cover healthcare institutions nationwide
• Distribution networks are the standard pathway for small-to-medium-scale importers to access the UAE market

Common Pitfalls and Risks

Pre-Registration Common Errors

1. Systematic underestimation of three-system registration costs: Many manufacturers entering the UAE market budget only for MOHAP registration costs, failing to consider the independent registration fees and agent service fees for DHA and DOH; the total cost of all three systems may be 2.5–3 times that of a single authority — the full cost must be incorporated in the market entry budget
2. Incomplete Agent Letter of Authorization authentication chain: This is one of the most common reasons for administrative review failure in UAE registration applications; each document's notarization and Apostille/Consular Legalization steps must be individually verified
3. ISO 13485 scope does not cover the product: The certificate scope does not explicitly cover the intended registered product; verify the certificate scope before registration
4. Insufficient labeling compliance preparation: Overlooking Arabic labeling requirements or poor Arabic translation quality, causing supplementary information delays
5. CPP/FSC validity management lapses: The CPP certificate validity period (typically 1 year) has expired without timely renewal, causing registration application materials to become invalid

Commercial and Contractual Risks

6. MA ownership risk: Similar to Saudi Arabia, UAE registration certificates are typically held in the agent's name; if the contract does not clearly protect the manufacturer's rights, the MA may be "controlled" by the agent; the contract must specify MA ownership and the agent's obligation to cooperate with certificate holder transfer upon termination
7. Three-system agent selection failure: Some agents have experience with one authority (e.g., MOHAP) but limited experience with another (e.g., DHA or DOH); when selecting an agent, evaluate their actual registration capability across all three systems
8. Documents not adapted across the three systems: The application forms and document formats differ slightly across the three systems; directly copying MOHAP application materials to DHA/DOH may result in failure of the administrative review

Technical Review Phase Risks

9. CE/FDA documents do not fully match the registered product specifications: The product models, indications, and specifications covered by the reference approval documents differ from the registered product; the differences must be explained in writing in the application; otherwise, the regulatory authority may refuse to accept the simplified review
10. Poor technical query response quality: Leads to multiple rounds of supplementary submissions, cumulatively causing delays of months
11. Neglecting independent maintenance of DHA/DOH registration certificates: After registration, only the MOHAP certificate is maintained while DHA/DOH annual fees and renewals are neglected, resulting in lapsed sales authorization in Dubai/Abu Dhabi

Recommended Market Entry Strategy

Preferred Pathway: CE/FDA + Parallel Registration with All Three Authorities

Step 1 (Foundation): Ensure holding valid EU CE (MDR/IVDR) and/or FDA 510(k)/PMA as the foundational documents for simplified review across all three UAE registration systems

Step 2 (Agent Arrangement): Appoint a local agent capable of handling all three registration systems (or separately appoint specialist regulatory agencies for each), and sign contracts protecting MA ownership

Step 3 (Parallel Applications): Simultaneously submit registration applications to MOHAP, DHA, and DOH to reduce overall waiting time; if resources are limited, prioritize based on target market: prioritize DHA if focused on Dubai private hospitals; prioritize DOH if focused on Abu Dhabi; prioritize MOHAP if focused on the five smaller emirates

Step 4 (Regional Linkage): After obtaining UAE registration, use UAE registration certificates as references to extend into neighboring MENA markets such as Jordan, Lebanon, and Egypt; simultaneously form a dual-anchor point with Saudi SFDA registration to maximize the regional coverage benefits of CE + SFDA + UAE

Market Entry Channel Recommendations

• High-end private hospitals (Cleveland Clinic Abu Dhabi, Mediclinic, etc.): Suitable for high-end specialist devices with CE + FDA dual certification; procurement decisions are relatively fast, and these institutions are willing to adopt innovative products with international clinical evidence
• Dubai Healthcare City (DHCC): As the UAE's healthcare business hub, DHCC is suitable as a platform for establishing Middle East regional distribution and partnership networks
• Public hospital procurement (SEHA/MOHAP): Suitable for standardized, cost-effective consumable devices; procurement decision cycles are longer and require advance preparation

Regional Strategy in Linkage with Saudi Registration

• If the product has already completed Saudi SFDA registration, citing SFDA review conclusions in DHA and MOHAP technical reviews produces a notable positive effect
• CE + SFDA + UAE triple-certificate combination is the most efficient certificate combination for MENA regional market coverage
• It is recommended to incorporate Saudi Arabia and UAE registration applications into a unified Middle East market entry roadmap, with coordinated planning of document preparation, authentication chains, and agent arrangements

---

Impact of Existing CE / FDA / NMPA Certificates

Quick Assessment

Certificate	Acceleration Effect	Key Mechanism
EU CE (MDR/IVDR)	⭐⭐⭐⭐	MOHAP/DHA/DOH all widely accept CE certificates as the core technical file foundation; substantive review shifts to procedural compliance verification
US FDA (510(k)/PMA)	⭐⭐⭐⭐	FDA approval is equally highly recognized alongside CE; FDA + CE combination carries a clear competitive advantage in high-end market procurement
China NMPA	⭐	UAE does not recognize NMPA as a reference market; no formal acceleration mechanism

EU CE (MDR/MDD/IVDR)

• Recognition Mechanism: UAE medical device regulation involves multiple authorities — MOHAP (Ministry of Health and Prevention) at the federal level, DHA (Dubai Health Authority) in Dubai, and DOH (Department of Health Abu Dhabi) in Abu Dhabi — all three authorities widely accept EU CE certificates. MOHAP requires a CE certificate or equivalent reference market approval document as a core component of the technical file; its internal review process, when the product holds a valid CE certificate, focuses on verifying local registration process compliance rather than independently re-reviewing technical data. DHA likewise has high acceptance of CE certificates, and basing registration application materials on CE technical files can substantially reduce supplementary information requests.
• Actual Effect: Products holding CE certificates experience genuine process simplification in reviews by all three UAE registration authorities; for manufacturers with CE certification, technical review queries typically focus on local labeling compliance and authorized agent arrangements rather than re-verification of product performance and safety. Overall, the review period can be shortened by 30%–50%.
• Key Caveats: The CE certificate must be from an EU-recognized Notified Body and within its validity period; products migrated to MDR are preferred over those still holding legacy MDD certificates; MOHAP requires the CE certificate to strictly correspond to the product models and specifications in the registration application — Technical File scope and certificate coverage must match; Arabic labeling is a mandatory UAE compliance requirement independent of CE certification — regardless of CE validity, Arabic labeling localization must be completed.

US FDA (510(k) / De Novo / PMA)

• Recognition Mechanism: FDA 510(k)/PMA approval is highly recognized by all three UAE regulatory authorities (MOHAP, DHA, DOH), with a status essentially equivalent to CE certificates. At the technical review level, FDA approval documents (Decision Letter + relevant technical summary) serve as the primary proof of product safety and efficacy, with the review focus similarly shifting to local procedural compliance verification.
• Actual Effect: The FDA + CE dual-certificate combination is particularly impactful in the UAE market, especially in procurement evaluations at high-end private medical institutions such as Dubai Healthcare City and Cleveland Clinic Abu Dhabi — FDA + CE dual certification is regarded as the highest quality endorsement, and procurement committee approval proceeds significantly faster; in MOH public hospital tenders, products with FDA approval typically have an advantage in technical scoring.
• Key Caveats: FDA documents must be currently valid (withdrawn or recalled 510(k)s are not accepted); if the product has FDA-mandated post-market studies (PMA Condition), this must be simultaneously disclosed to UAE regulatory authorities; UAE has Arabic labeling and IFU requirements — English-language FDA-approved labels must be localized through professional translation.

China NMPA (National Medical Products Administration)

• Recognition Mechanism: MOHAP, DHA, and DOH do not list China's NMPA as a formal reference market. NMPA certificates do not have formal review-acceleration effect in UAE registration applications and cannot trigger any simplified review pathway.
• Actual Effect: No formal acceleration effect. Chinese manufacturers holding only NMPA certificates without CE or FDA must follow the full documentation review pathway, at the same review intensity as products with no foreign approvals at all; NMPA certificates may be submitted as supplementary reference information indicating "approved in another market," but do not produce any substantive pathway difference.
• Key Caveats: The optimal strategy for Chinese manufacturers entering the UAE market is to first obtain EU CE certification, then use the CE certificate to advance MOHAP/DHA/DOH registration; Chinese-invested medical companies in the UAE are growing rapidly, and market competition is intensifying — CE certification is a baseline threshold for UAE market entry.

Practical Recommendations

1. Multi-authority parallel registration strategy: The UAE has three relatively independent registration systems (MOHAP/DHA/DOH); when holding CE certificates, it is recommended to apply to all three systems simultaneously to avoid sequential applications causing time accumulation; the three certificates respectively cover different healthcare institution channels (MOHAP covers most national hospitals, DHA covers Dubai private hospitals, DOH covers Abu Dhabi healthcare institutions)
2. Arabic compliance as an independent workstream: Arabic labeling and IFU localization are mandatory UAE requirements independent of CE; this work should be initiated at the very start of registration to avoid labeling compliance issues delaying the overall timeline
3. High-end market entry point: FDA + CE dual-certificate manufacturers can prioritize targeted entry into Dubai Healthcare City (DHCC) and Abu Dhabi medical institutions — procurement evaluations at these institutions place extremely high importance on international certification endorsements, making them high-value entry points for the UAE market
4. Regional linkage value: UAE (especially MOHAP) registration certificates carry certain reference value for neighboring markets such as Jordan and Lebanon; combining UAE and Saudi SFDA applications (using CE as the foundation) can build a dual-anchor registration strategy for the MENA region

AR / Local Representative Special Note

UAE is not a contact-only representative model. Foreign manufacturers generally need a UAE licensed establishment / local authorized representative to handle MOHAP/EDE medical equipment registration, importation, and trading execution. The local party may control the e-service account, registration certificate, and import/trading pathway.

Special reminder: MOHAP has transferred selected services to the Emirates Drug Establishment (EDE). Before market entry, verify both the federal MOHAP/EDE route and any Dubai / Abu Dhabi access requirements, and write account control, certificate ownership, import permits, variations, termination, and handover into the authorization agreement.

Verification file: [[docs/seo/ar-verification/uae|UAE AR verification]]

Official Sources and Verification Date

• Emirates Drug Establishment (EDE): https://www.ede.gov.ae
• Ministry of Health and Prevention (MOHAP): https://mohap.gov.ae
• Dubai Health / Dubai Health Authority: https://www.dha.gov.ae
• Department of Health Abu Dhabi: https://www.doh.gov.ae
• Dubai Healthcare City: https://dhcc.ae
• U.S. International Trade Administration country guide: https://www.trade.gov/country-commercial-guides
• Gulf Drug: https://www.gulfdrug.com
• Al Hayat Pharmaceuticals: https://www.alhayatuae.com
• MPC Healthcare: https://www.mpchealthcare.com

Updated: 2026-07-02. The market analysis is based on official regulatory portals, Dubai / Abu Dhabi healthcare-system public materials, trade-promotion materials, and public information from major local channel companies. Because medical device registration services are in an EDE / MOHAP transition period, verify the latest e-service entry point again before filing.